{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T23:46:25Z","timestamp":1790552785541,"version":"4.1.0"},"reference-count":43,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,2,1]],"date-time":"2019-02-01T00:00:00Z","timestamp":1548979200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2020,1,12]],"date-time":"2020-01-12T00:00:00Z","timestamp":1578787200000},"content-version":"am","delay-in-days":345,"URL":"http:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100006364","name":"Institut National du Cancer INCa","doi-asserted-by":"publisher","award":["PRT-K2017-072"],"award-info":[{"award-number":["PRT-K2017-072"]}],"id":[{"id":"10.13039\/501100006364","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004099","name":"Ligue contre le Cancer","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100004099","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100011074","name":"University of Lyon","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100011074","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","ejcancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Cancer"],"published-print":{"date-parts":[[2019,2]]},"DOI":"10.1016\/j.ejca.2018.12.011","type":"journal-article","created":{"date-parts":[[2019,1,14]],"date-time":"2019-01-14T08:38:24Z","timestamp":1547455104000},"page":"55-60","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":26,"special_numbering":"C","title":["Neoepitopes-based vaccines: challenges and perspectives"],"prefix":"10.1016","volume":"108","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1843-6286","authenticated-orcid":false,"given":"Vincent","family":"Alcazer","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Bonaventura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurie","family":"Tonon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sandrine","family":"Wittmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christophe","family":"Caux","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Depil","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejca.2018.12.011_bib1","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aaf0685","article-title":"The human vaccines project: a roadmap for cancer vaccine development","volume":"8","author":"Romero","year":"2016","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib2","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1038\/nri.2017.131","article-title":"Towards personalized, tumour-specific, therapeutic vaccines for cancer","volume":"18","author":"Hu","year":"2018","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ejca.2018.12.011_bib3","doi-asserted-by":"crossref","DOI":"10.1056\/NEJMc1508163","article-title":"Genetic basis for clinical response to CTLA-4 blockade in melanoma","volume":"373","author":"Chan","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib4","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S1470-2045(15)70054-9","article-title":"Activity and safety of nivolumab, an anti-PD-1 immune checkpoint inhibitor, for patients with advanced, refractory squamous non-small-cell lung cancer (CheckMate 063): a phase 2, single-arm trial","volume":"16","author":"Rizvi","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.12.011_bib5","doi-asserted-by":"crossref","first-page":"2509","DOI":"10.1056\/NEJMoa1500596","article-title":"PD-1 blockade in tumors with mismatch-repair deficiency","volume":"372","author":"Le","year":"2015","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib6","doi-asserted-by":"crossref","first-page":"2500","DOI":"10.1056\/NEJMc1713444","article-title":"Tumor mutational burden and response rate to PD-1 inhibition","volume":"377","author":"Yarchoan","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib7","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/j.celrep.2016.12.019","article-title":"Pan-cancer immunogenomic analyses reveal genotype-immunophenotype relationships and predictors of response to checkpoint blockade","volume":"18","author":"Charoentong","year":"2017","journal-title":"Cell Rep"},{"key":"10.1016\/j.ejca.2018.12.011_bib8","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nature10755","article-title":"Cancer exome analysis reveals a T-cell-dependent mechanism of cancer immunoediting","volume":"482","author":"Matsushita","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.12.011_bib9","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1186\/s13073-016-0288-x","article-title":"NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets","volume":"8","author":"Nielsen","year":"2016","journal-title":"Genome Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib10","doi-asserted-by":"crossref","first-page":"5586","DOI":"10.4049\/jimmunol.153.12.5586","article-title":"The relationship between class I binding affinity and immunogenicity of potential cytotoxic T cell epitopes","volume":"153","author":"Sette","year":"1994","journal-title":"J Immunol"},{"key":"10.1016\/j.ejca.2018.12.011_bib11","doi-asserted-by":"crossref","first-page":"e439","DOI":"10.1200\/JCO.2012.47.7521","article-title":"Tumor exome analysis reveals neoantigen-specific T-cell reactivity in an ipilimumab-responsive melanoma","volume":"31","author":"van Rooij","year":"2013","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ejca.2018.12.011_bib12","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pcbi.1003266","article-title":"Properties of MHC class I presented peptides that enhance immunogenicity","volume":"9","author":"Calis","year":"2013","journal-title":"PLoS Comput Biol"},{"key":"10.1016\/j.ejca.2018.12.011_bib13","article-title":"Neopepsee: accurate genome-level prediction of neoantigens by harnessing sequence and amino acid immunogenicity information","author":"Kim","year":"2018","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.12.011_bib14","doi-asserted-by":"crossref","DOI":"10.1038\/nature24473","article-title":"A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy","author":"\u0141uksza","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.12.011_bib15","doi-asserted-by":"crossref","first-page":"572","DOI":"10.1038\/nature14001","article-title":"Predicting immunogenic tumour mutations by combining mass spectrometry and exome sequencing","volume":"515","author":"Yadav","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.12.011_bib16","doi-asserted-by":"crossref","first-page":"13404","DOI":"10.1038\/ncomms13404","article-title":"Direct identification of clinically relevant neoepitopes presented on native human melanoma tissue by mass spectrometry","volume":"7","author":"Bassani-Sternberg","year":"2016","journal-title":"Nat Commun"},{"key":"10.1016\/j.ejca.2018.12.011_bib17","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature14426","article-title":"Mutant MHC class II epitopes drive therapeutic immune responses to cancer","volume":"520","author":"Kreiter","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.12.011_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.122467","article-title":"Enhanced detection of neoantigen-reactive T cells targeting unique and shared oncogenes for personalized cancer immunotherapy","volume":"3","author":"Yossef","year":"2018","journal-title":"JCI Insight"},{"key":"10.1016\/j.ejca.2018.12.011_bib19","doi-asserted-by":"crossref","first-page":"3153","DOI":"10.4161\/21645515.2014.980686","article-title":"DNA vaccine for cancer immunotherapy","volume":"10","author":"Yang","year":"2014","journal-title":"Hum Vaccines Immunother"},{"key":"10.1016\/j.ejca.2018.12.011_bib20","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1126\/science.1093620","article-title":"Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8","volume":"303","author":"Heil","year":"2004","journal-title":"Science"},{"key":"10.1016\/j.ejca.2018.12.011_bib21","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1080\/14760584.2018.1434000","article-title":"Current challenges for cancer vaccine adjuvant development","volume":"17","author":"Bowen","year":"2018","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.ejca.2018.12.011_bib22","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1038\/nm.2883","article-title":"Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival","volume":"18","author":"Walter","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib23","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1038\/nrc2373","article-title":"Immunotherapy of established (pre)malignant disease by synthetic long peptide vaccines","volume":"8","author":"Melief","year":"2008","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2018.12.011_bib24","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1038\/nrmicro2240","article-title":"Viruses as vaccine vectors for infectious diseases and cancer","volume":"8","author":"Draper","year":"2010","journal-title":"Nat Rev Microbiol"},{"key":"10.1016\/j.ejca.2018.12.011_bib25","doi-asserted-by":"crossref","first-page":"803","DOI":"10.1126\/science.aaa3828","article-title":"A dendritic cell vaccine increases the breadth and diversity of melanoma neoantigen-specific T cells","volume":"348","author":"Carreno","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.ejca.2018.12.011_bib26","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1126\/science.aaf1490","article-title":"Clonal neoantigens elicit T cell immunoreactivity and sensitivity to immune checkpoint blockade","volume":"351","author":"McGranahan","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejca.2018.12.011_bib27","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1038\/nature23003","article-title":"Personalized RNA mutanome vaccines mobilize poly-specific therapeutic immunity against cancer","volume":"547","author":"Sahin","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.12.011_bib28","doi-asserted-by":"crossref","first-page":"1337","DOI":"10.1126\/science.aaf2288","article-title":"Targeting of cancer neoantigens with donor-derived T cell receptor repertoires","volume":"352","author":"Stronen","year":"2016","journal-title":"Science"},{"key":"10.1016\/j.ejca.2018.12.011_bib29","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1056\/NEJMoa1604958","article-title":"Mutations associated with acquired resistance to PD-1 blockade in melanoma","volume":"375","author":"Zaretsky","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib30","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1016\/j.cell.2017.10.001","article-title":"Allele-specific HLA loss and immune escape in lung cancer evolution","volume":"171","author":"McGranahan","year":"2017","journal-title":"Cell"},{"key":"10.1016\/j.ejca.2018.12.011_bib31","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2018.12.011_bib32","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1126\/science.aaf1292","article-title":"T cell costimulatory receptor CD28 is a primary target for PD-1\u2013mediated inhibition","volume":"355","author":"Hui","year":"2017","journal-title":"Science"},{"key":"10.1016\/j.ejca.2018.12.011_bib33","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ccell.2018.07.001","article-title":"Comprehensive analysis of alternative splicing across tumors from 8,705 patients","volume":"34","author":"Kahles","year":"2018","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejca.2018.12.011_bib34","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1016\/S1470-2045(17)30516-8","article-title":"Insertion-and-deletion-derived tumour-specific neoantigens and the immunogenic phenotype: a pan-cancer analysis","volume":"18","author":"Turajlic","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ejca.2018.12.011_bib35","first-page":"a028829","article-title":"Is it possible to develop cancer vaccines to neoantigens, what are the major challenges, and how can these Be overcome?: neoantigens: nothing new in spite of the name","author":"Finn","year":"2017","journal-title":"Cold Spring Harb Perspect Biol"},{"key":"10.1016\/j.ejca.2018.12.011_bib36","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/nature22991","article-title":"An immunogenic personal neoantigen vaccine for patients with melanoma","volume":"547","author":"Ott","year":"2017","journal-title":"Nature"},{"key":"10.1016\/j.ejca.2018.12.011_bib37","doi-asserted-by":"crossref","DOI":"10.1093\/jnci\/djw261","article-title":"Role of antigen spread and distinctive characteristics of immunotherapy in cancer treatment","volume":"109","author":"Gulley","year":"2017","journal-title":"JNCI J Natl Cancer Inst"},{"key":"10.1016\/j.ejca.2018.12.011_bib38","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nrc3973","article-title":"Evolving synergistic combinations of targeted immunotherapies to combat cancer","volume":"15","author":"Melero","year":"2015","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ejca.2018.12.011_bib39","doi-asserted-by":"crossref","DOI":"10.1093\/annonc\/mdx302.003","article-title":"LBA-004Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC)","volume":"28","author":"Argil\u00e9s","year":"2017","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ejca.2018.12.011_bib40","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1158\/0008-5472.CAN-11-3912","article-title":"Regulatory T cell modulation using cyclophosphamide in vaccine approaches: a current perspective","volume":"72","author":"Le","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ejca.2018.12.011_bib41","doi-asserted-by":"crossref","first-page":"3856","DOI":"10.3390\/cancers3043856","article-title":"Cytokines in cancer immunotherapy","volume":"3","author":"Lee","year":"2011","journal-title":"Cancers"},{"key":"10.1016\/j.ejca.2018.12.011_bib42","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1038\/nm.4200","article-title":"Eradication of large established tumors in mice by combination immunotherapy that engages innate and adaptive immune responses","volume":"22","author":"Moynihan","year":"2016","journal-title":"Nat Med"},{"key":"10.1016\/j.ejca.2018.12.011_bib43","doi-asserted-by":"crossref","first-page":"1382","DOI":"10.1158\/2159-8290.CD-16-0577","article-title":"Improved efficacy of neoadjuvant compared to adjuvant immunotherapy to eradicate metastatic disease","volume":"6","author":"Liu","year":"2016","journal-title":"Cancer Discov"}],"container-title":["European Journal of Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315570?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0959804918315570?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T20:22:53Z","timestamp":1760732573000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0959804918315570"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2]]},"references-count":43,"alternative-id":["S0959804918315570"],"URL":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.011","relation":{},"ISSN":["0959-8049"],"issn-type":[{"value":"0959-8049","type":"print"}],"subject":[],"published":{"date-parts":[[2019,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Neoepitopes-based vaccines: challenges and perspectives","name":"articletitle","label":"Article Title"},{"value":"European Journal of Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejca.2018.12.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}